title: [Metformin can reduce the risk of colorectal cancer].
abstract: Diabetes mellitus (DM) is an established, independent risk factor for colorectal cancer (CRC). Metformin is the first drug of choice for type 2 DM. Several studies have shown a decreased risk of developing CRC in patients with metformin-treated DM, compared with patients with diabetes not treated with metformin. An increased overall survival and CRC-specific survival in patients with CRC and metformin-treated DM has still not been substantially proven. Further studies are needed before a conclusion can be made whether metformin should be used in the treatment of CRC.
authors.affiliation: Kirurgisk Forskningsenhed, Kirurgisk Afdeling, Køge Sygehus, Lykkebækvej 1, 4600 Køge. tifer@regionsjaelland.dk.
authors.forename: Tina
authors.initials: T
authors.lastname: Fransgård
authors.forename: Ismail
authors.initials: I
authors.lastname: Gögenur
mesh_terms: D015179:Colorectal Neoplasms / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008687:Metformin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin